SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Cocrystal Pharma, Inc. (Nasdaq: COCP), f/k/a/ BioZone Pharmaceuticals, Inc., To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit – iCrowdNewswire
  • Spain
  • Brazil
  • Russia
  • France
  • Germany
  • China
  • Korea
  • Japan
 
x

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Oct 11, 2018 2:00 PM ET

Subject to Terms of Use.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Cocrystal Pharma, Inc. (Nasdaq: COCP), f/k/a/ BioZone Pharmaceuticals, Inc., To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

Legal Newswire iCrowdNewswire - Oct 11, 2018

STEVENSON, Md., — The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) and/or Cocrystal’s predecessor, BioZone Pharmaceuticals, Inc., securities during the period between September 23, 2013 through September 7, 2018, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until November 19, 2018 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Cocrystal securities during the Class Period.  Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that certain individuals associated with Cocrystal Pharma were engaged in a pump-and-dump scheme and the Company failed to abide by U.S. Securities and Exchange Commission’s (“SEC”) disclosure regulations.

According to the complaint, following a September 7, 2018 SEC press release announcing charges for the pump and dump schemes, the value of Cocrystal Pharma shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Cocrystal securities purchased on or after September 23, 2013 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.

Contact Information:

Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]

View Related News >